» Articles » PMID: 26603890

Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin

Overview
Journal AAPS J
Specialty Pharmacology
Date 2015 Nov 26
PMID 26603890
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Colistin is often the only effective antibiotic against the respiratory infections caused by multidrug-resistant Gram-negative bacteria. However, colistin-resistant multidrug-resistant isolates have been increasingly reported and combination therapy is preferred to combat resistance. In this study, five combination formulations containing colistin (COL) and rifampicin (RIF) were prepared by spray drying. The lowest minimum inhibitory concentration (MIC) value against Pseudomonas aeruginosa PAO1 was measured for the formulation of COL/RIF = 4:1 with relatively high emitted doses (over 80%) and satisfactory fine particle fractions (over 60%). Data from X-ray photoelectron spectroscopy (XPS) and nano-time-of-flight secondary ion mass spectrometry (ToF-SIMS) showed the surfaces of particles were mainly covered by rifampicin even for the formulation with a mass ratio of COL/RIF = 4:1. Because colistin is hygroscopic and rifampicin is hydrophobic, moisture absorption of combination formulations was significantly lower than the pure colistin formulation in the dynamic vapour sorption results. To investigate the dissolution characteristics, four dissolution test methods (diffusion Franz cell, modified Franz cell, flow-through and beaker methods) were employed and compared. The modified Franz cell method was selected to test the dissolution behaviour of aerosolised powder formulations to eliminate the effect of membrane on dissolution. The results showed that surface enrichment of hydrophobic rifampicin neither affected aerosolisation nor retarded dissolution rate of colistin in the combination formulations. For the first time, advanced surface characterisation techniques of XPS and ToF-SIMS have shown their capability to understand the effect of surface composition on the aerosolisation and dissolution of combination powders.

Citing Articles

Impact of Co-Spray Drying with Leucine or Trileucine on Aerosol Performance, In Vitro Dissolution, and Cellular Uptake of Colistin Powder Formulations for Inhalation.

Huang Y, Arte K, Patil C, Zhou Q, Qu L Pharmaceutics. 2025; 17(2).

PMID: 40006566 PMC: 11858924. DOI: 10.3390/pharmaceutics17020199.


Preparation and Evaluation of Inhalable Microparticles with Improved Aerodynamic Performance and Dispersibility Using L-Leucine and Hot-Melt Extrusion.

Jeong J, Kim J, Choi Y, Shin D, Kang J, Kim D Pharmaceutics. 2024; 16(6).

PMID: 38931905 PMC: 11206964. DOI: 10.3390/pharmaceutics16060784.


Design of Experiment (DoE) Approach for Developing Inhalable PLGA Microparticles Loaded with Clofazimine for Tuberculosis Treatment.

Rongala D, Patil S, Kunda N Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931422 PMC: 11206430. DOI: 10.3390/ph17060754.


Inhalable Nanoparticle-based Dry Powder Formulations for Respiratory Diseases: Challenges and Strategies for Translational Research.

Chan H, Chow S, Zhang X, Zhao Y, Tong H, Chow S AAPS PharmSciTech. 2023; 24(4):98.

PMID: 37016029 PMC: 10072922. DOI: 10.1208/s12249-023-02559-y.


Co-Delivery of D-LAK Antimicrobial Peptide and Capreomycin as Inhaled Powder Formulation to Combat Drug-Resistant Tuberculosis.

Shao Z, Chow M, Chow S, Lam J Pharm Res. 2023; 40(5):1073-1086.

PMID: 36869245 PMC: 9984245. DOI: 10.1007/s11095-023-03488-y.


References
1.
OHara P, Hickey A . Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res. 2000; 17(8):955-61. DOI: 10.1023/a:1007527204887. View

2.
Lavorini F, Magnan A, Dubus J, Voshaar T, Corbetta L, Broeders M . Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2007; 102(4):593-604. DOI: 10.1016/j.rmed.2007.11.003. View

3.
Henwood S, Liebenberg W, Tiedt L, Lotter A, de Villiers M . Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates. Drug Dev Ind Pharm. 2002; 27(10):1017-30. DOI: 10.1081/ddc-100108364. View

4.
Davies N, Feddah M . A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm. 2003; 255(1-2):175-87. DOI: 10.1016/s0378-5173(03)00091-7. View

5.
York P . Analysis of moisture sorption hysteresis in hard gelatin capsules, maize starch, and maize starch: drug powder mixtures. J Pharm Pharmacol. 1981; 33(5):269-73. DOI: 10.1111/j.2042-7158.1981.tb13779.x. View